Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical development program was initiated in 2007 to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. If LUMINATE is successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition

Anglade, Eddy

Aspeslet, Launa J

Weiss, Sidney L

English

PubMed

Eddy Anglade1, Launa J Aspeslet2, Sidney L Weiss11Lux Biosciences Inc., Jersey City, NJ, USA; 2Isotechnika Inc., Edmonton, AB, CanadaAbstract: Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical development program was initiated in 2007 to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. If LUMINATE is successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition.Keywords: voclosporin, calcineurin inhibitors, LX211, LUMINATE trials, ophthalmic diseases, uveitis, ISA24

Eddy Anglade

Launa J Aspeslet

Sidney L Weiss

Directory of Open Access Journals

Clinical Ophthalmology

A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin

24 Week results of a Phase III randomized, double-blind, multicentre, placebo-controlled study of ISA247 in plaque psoriasis [abstract].

A Phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients [abstract].

Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet,

Cyclosporine A and tacrolimus (FK-506) immunosuppression through immunophilin-dependent inhibition of calcineurin function. In: Lieberman R, Mukherjee A (Ed).

Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial ﬁ broblasts.

Data on ﬁ le.

Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters. Transplant Proc,

for the PROMISE Study Investigators.

Guidelines for the use of immunosuppressive drugs in patients with ocular inﬂ ammatory disorders: Recommendations of an expert panel.

Immunosuppression for posterior uveitis.

In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates.

Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.

ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247,

ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc,

ISA247 A new generation calcineurin inhibitor [abstract].

ISA247 Remains a safe and efﬁ cacious agent after 48 weeks of continuous therapy: interim results of the SPIRIT Extension Study [abstract].

ISA247: Preliminary results of a phase IIb multicentre, de novo renal transplant trial [abstract].

Pharmacokinetics and pharmacodynamics of ISA247 in a Phase III randomized, multicenter, double-blind, placebo-controlled study [abstract].

Pharmacokinetics and pharmacodynamics of ISA247 in a Phase III, randomized, multicentre, double-blind, placebo-controlled study [abstract].

Pharmacokineticspharmacodynamics and safety of Trans-ISA247: A novel immunosuppressant [abstract].

Phase 2 randomized, multicenter, open-label study of ISA247 and Neoral in post-renal transplant patients [abstract].

Phase 2 trial results of ISATX247, a novel calcineurin inhibitor with a therapeutic window [abstract].

Phase I study summaries.

Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Subcutaneous injections of LX211 prevent and reverse experimental autoimmune uveoretinitis in rats [poster].

The mechanism of action of cyclosporin A and FK-506. Gr Immunol Today,

The mechanism of action of cyclosporin A and FK506.

The natural history of uveitis.

The novel immunosuppressant ISA247 demonstrates a different metabolic proﬁ le than cyclosporine A in vitro and in vivo [abstract].

http://doaj.org/search?source=%7B%22query%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22term%22%3A%7B%22id%22%3A%22801e6176649a4aa99f9d6d2511d1be30%22%7D%7D%5D%7D%7D%7D

A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals